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Anesthesiologists have been aware of the importance of optimal drug combination long ago and performed many 
investigations about the combined use of anesthetic agents.  There are 3 classes of drug interaction: additive, 
synergistic, and antagonistic.  These definitions of drug interaction suggest that a zero interaction model should exist 
to be used as a reference in classifying the interaction of drug combinations.  The Loewe additivity has been used as a 
universal reference model for classifying drug interaction.  Most anesthetic drugs follow the sigmoid Emax model (Hill 
equation); this model will be used for modeling response surface.  Among lots of models for drug interaction in the 
anesthetic area, the Greco model, Machado model, Plummer model, Carter model, Minto model, Fidler model, and 
Kong model are adequate to be applied to the data of anesthetic drug interaction.  A model with a single interaction 
parameter does not accept an inconsistency in the classes of drug interactions.  To solve this problem, some 
researchers proposed parametric models which have a polynomial interaction function to capture synergy, additivity, 
and antagonism scattered all over the surface of drug combinations.  Inference about truth must be based on an 
optimal approximating model.  Akaike information criterion (AIC) is the most popular approach to choosing the best 
model among the aforementioned models.  Whatever the good qualities of a chosen model, it is uncertain whether 
the chosen model is the best model.  A more robust inference can be extracted from averaging several models that 
are considered relevant.  (Korean J Anesthesiol 2010; 58: 421-434)
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surface model.
Drug interaction: focusing on response surface models
Soo-il Lee
Department of Anesthesiology and Pain Medicine, Dong-A University Medical College, Busan, Korea
Received: April 26, 2010.  Revised: April 29, 2010.  Accepted: April 29, 2010.
Corresponding author: Soo-il Lee, M.D., Ph.D., Department of Anesthesiology and Pain Medicine, Dong-A University Medical College, 3-1, 
Dongdaesin-dong, Seo-gu, Busan 602-715, Korea. Tel: 82-51-240-5390, Fax: 82-51-247-7819, E-mail: silee@dau.ac.kr
This work was supported by the Dong-A University research fund.
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC422 www.ekja.org
Drug interaction Vol. 58, No. 5, May 2010
Introduction
    In anesthesia, a synergistic effect of the combined treatments 
gives patients the following favorable outcomes: increasing the 
efficacy of the anesthetic effect, reducing doses while increasing 
or maintaining the same efficacy to avoid toxicity of anesthetic 
drugs, minimizing or slowing the development of drug 
resistance, and providing selective synergism against the target 
(or efficacy synergism) versus the host (or toxicity antagonism) 
[1]. Many such studies can be found in related literature [2-8]. 
    There are 3 classes of drug interaction: additive interaction, 
in which the response of a drug combination is just what 
is expected from the dose-response relationships of drugs; 
synergistic interaction, in which the response is greater than 
expected; and antagonistic interaction, in which the response 
is less than expected. There is no uniform agreement on the 
terminology of drug interaction. Synonyms for what is termed 
additive interaction are zero, or null interaction, independence 
(Bliss), and indifference. Synonyms for synergistic interaction 
are positive or supra-additive interaction, potentiation, 
and augmentation. Synonyms for antagonistic interaction 
are negative, infra-additive or subadditive interaction, and 
negative synergy. These definitions of drug interaction suggest 
that a zero interaction model should exist to be used as a 
reference in classifying the interaction of drug combinations. 
A pharmacodynamic model of most anesthetic drugs is 
the sigmoid Emax model (Hill equation); let’s discuss drug 
interactions and response surface focusing on this model.
Reference models for zero interaction
    Because the classification of drug interactions is determined 
as a greater or less pharmacological effect of a two-drug 
combination than what would be predicted for zero interaction 
from the knowledge of the effects of each drug individually, 
its determination absolutely depends on the reference model 
of zero interaction. A review by Berenbaum [9] has listed 8 
approaches, and another review by Greco et al. [10] categorized 
13 approaches and methods for determining the class of drug 
interaction. To define the class of drug interactions, first, an 
adequate reference model of additive (or zero) interaction 
should be established as a universal standard reference. 
Historically, 3 zero interaction models are commonly used 
[9,10]: Bliss independence [11], Loewe additivity [12], and the 
median-effect method from the law of mass action [13]. 
Bliss independence
    Bliss independence implies that 2 drugs do not pharma-
cologically or physiologically cooperate with each other for 
each drug behaves independently of the other [10]. The general 
equations of Bliss independence (Eq. (1)) and a specific one (Eq. 
(2)), which assumes that a sigmoid Emax relationship [14,15] is 
an appropriate pharmacodynamic model for each drug, are as 
follows: 
   Fu12 = fu1 × fu2 --------------------------------------------------- (1)
6 
 
Fu12 = fu1×fu2 ---------------------------- (1) 
E�E�
E����E�
�
����
��
ED����
�
�γ�
�����
��
ED����
�
�γ�
�
 --------- (2). 
In Eq. (1), fu1, fu2, and fu12 are the fractions of response for drug 1, drug 2, and combination 
unaffected.[16] In Eq. (2), 
E�E�
E����E�
 is a fraction of effect resulting from the mixture of d1 and d2, d1 
and d2 are doses of each drug in the mixture that yield an effect E, ED50,1 or 2 is dose of drugs to 
produce 50% of maximal effect (Emax) for each drug acting alone, and γ1 and γ2 are Hill coefficients 
(slope of dose-response curve). When Eq. (1) and (2) are recast in terms of the fraction of effect 
affected (fa1 or 2) (if 1 − fa exchanges fu in Eq. (1), because fa + fu = 1), then Eq. (3) and (4) are the 
results.  
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Eq. (3) is similar to the equation of probabilities of independent events.[17] The curvature of 
Bliss independence line depends on Hill coefficient of each drug (Fig. 1).  
2.2  Loewe Additivity 
Lines connecting points representing equi-effective dose combinations are termed isoboles 
(Fig.  1).  They  were  introduced  by  Fraser,  [18,19]  who  claimed  that,  in  using  this  device  for 
evaluating the antagonism between the actions of physostigmine and atropine, “the results of the 
experiment will be rendered apparent by a mere glance at the diagram.” Loewe extended this 
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6 
 
Fu12 = fu1×fu2 ---------------------------- (1) 
E�E�
E����E�
�
����
��
ED����
�
�γ�
�����
��
ED����
�
�γ�
�
 --------- (2). 
In Eq. (1), fu1, fu2, and fu12 are the fractions of response for drug 1, drug 2, and combination 
unaffected.[16] In Eq. (2), 
E�E�
E����E�
 is a fraction of effect resulting from the mixture of d1 and d2, d1 
and d2 are doses of each drug in the mixture that yield an effect E, ED50,1 or 2 is dose of drugs to 
produce 50% of maximal effect (Emax) for each drug acting alone, and γ1 and γ2 are Hill coefficients 
(slope of dose-response curve). When Eq. (1) and (2) are recast in terms of the fraction of effect 
affected (fa1 or 2) (if 1 − fa exchanges fu in Eq. (1), because fa + fu = 1), then Eq. (3) and (4) are the 
results.  
Fa12 = fa1 + fa2 − fa1 × fa2 ----------------------- (3) 
E�E�
E����E�
�
��
ED����
�
�γ�
��
��
ED����
�
�γ�
��
��
ED����
�
�γ�
�
��
ED����
�
�γ�
����
��
ED����
�
�γ�
�����
��
ED����
�
�γ�
�
 ----- (4) 
Eq. (3) is similar to the equation of probabilities of independent events.[17] The curvature of 
Bliss independence line depends on Hill coefficient of each drug (Fig. 1).  
2.2  Loewe Additivity 
Lines connecting points representing equi-effective dose combinations are termed isoboles 
(Fig.  1).  They  were  introduced  by  Fraser,  [18,19]  who  claimed  that,  in  using  this  device  for 
evaluating the antagonism between the actions of physostigmine and atropine, “the results of the 
experiment will be rendered apparent by a mere glance at the diagram.” Loewe extended this 
 is a 
fraction of the effect resulting from the mixture of d1 and d2; d1 
and d2 are doses of each drug in the mixture that yield the effect 
E; ED50,1 or 2 is a dose of drugs to produce 50% of the maximal 
effect (Emax) for each drug acting alone; and γ 1 and γ 2 are Hill 
coefficients (slope of dose-response curve). When Eq. (1) and (2) 
are recast in terms of the fraction of effect affected (fa1 or 2) (if 1 - 
fa exchanges fu in Eq. (1), because fa + fu = 1), then Eq. (3) and 
(4) are the results. 
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    Eq. (3) is similar to the equation of probabilities of independent 
events [17]. The curvature of the Bliss independence line 
depends on the Hill coefficient of each drug (Fig. 1). 
Fig. 1. Normalized isoboles at 50% effect level, for the Bliss 
independence model, Eq. (2), for various values of γ 1 and γ 2, which 
are listed next to each corresponding curve. A single γ indicates 
that γ 1 = γ 2 = γ. When Hill coefficients are different (one larger than 
1.3 and the other less than 1.2), the isoboles are S-shaped and may 
cross the Loewe additivity diagonal line. The solid diagonal line is 
the Loewe additivity line (Eq. (5)). The isobole for zero interaction of 
a mutually nonexclusive model (Eq. (9)) is the same curve as that of 
the Bliss independence model with γ  = 1.0.423 www.ekja.org
Korean J Anesthesiol Soo-il Lee
Loewe additivity
    Lines connecting points representing equi-effective dose 
combinations are termed isoboles (Fig. 1). They were intro-
duced by Fraser [18,19], who claimed that, in using this device for 
evaluating the antagonism between the actions of physostig-
mine and atropine, “the results of the experiment will be 
rendered apparent by a mere glance at the diagram.” Loewe 
extended this method to synergism [12,20]. Loewe used a 
straight line isobole for zero interaction when the combined 
drugs had similar mechanisms of action and similar dose-
response relationship, and asserted that the isobole would be 
curved when combined drugs had different mechanisms of 
action and dissimilar dose-response relationship. Recently, 
Tallarida [21] supported Loewe’s assertion. When a full agonist 
and a partial agonist have different maximum values, or when 
Hill coefficients (γ of sigmoid Emax model) of two full agonist 
drugs are different, each case has a varying potency ratio. For a 
full agonist and a partial agonist, the isobole of no interaction 
is no longer straight but curved [22]. For two full agonists with 
a varying potency, termed “heterodynamic” by Loewe [12], the 
application of dose equivalence leads to not just one, but to 
two nonlinear additive isoboles [21,23]. However, Berenbaum 
[9] maintained that a straight-line isobole is appropriate for 
a zero interactive combination, for it is not derived from the 
knowledge of the shapes of the dose-response curves or of 
their mechanisms of action, and he concluded that it is valid 
irrespective of the shapes of these curves, similar or dissimilar, 
and also, irrespective of their mechanisms of action. Although 
the shape of the isobole for Loewe additivity remains to be 
further studied, a straight line of additivity is commonly 
employed to distinguish synergistic and antagonistic from 
additive interactions. Although there are many reasons to prefer 
the Berenbaum method, the most predominate reason to use it 
may be because of easy calculations.
    The general equation of the Loewe additivity (Eq. (5)) and 
a specific form (Eq. (6)), which assumes that a sigmoid Emax 
relationship is appropriate for each drug, is defined as
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If the interaction index at (d1, d2) is equal to, less than, or greater than 1, the combination dose is 
asserted to be additive, synergistic, or antagonistic, respectively.  
2.3  Median-effect method from the law of mass action 
The median-effect principle (Eq. (7)) was originated by Chou. [24,25] The median-effect 
equation describes dose-response relationship in the simplest terms, which is given by  
f� f� ⁄ � f� �� � f�� ⁄ � �d D� ⁄ �� � � � � � � � � � � � � � � � � � � � � � ��8�,  
where d is the dose of a drug, fa is the fraction affected by d, fu is the fraction of unaffected by d 
(i.e., fu = 1 − fa, and fa / fu = odds ratio), Dm is the median effect dose (e.g. EC50, or ED50), and m is 
the slope coefficient of dose-response curve. When m is greater than 1, the dose-response curve 
becomes S-shaped, so m is equivalent to Hill coefficient of sigmoid Emax equation. 
Chou and Talalay [16] extended the median-effect equation for a single drug to multiple drugs. 
Thus, for a two-drug interaction, they got the same equation of combination index (CI) (Eq. (8)) as 
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    As shown in Fig. 1, the isobole of CI for the mutually nonex-
clusive model is concave upward, and is identical to that of the 
Bliss independence model (Eq. (4)) in which the Hill coefficient 
(γ) of sigmoid Emax model is 1. Therefore, this model under  esti-
mates synergistic effects.424 www.ekja.org
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    Because partially exclusive or partially nonexclusive cases may 
exist, and the equation with the third term may underestimate 
synergistic effects, Chou [1] claimed that the equation without 
the third term should be used as the “base equation” and that 
mutual non-exclusivity should be used as a contributing factor 
for the intrinsic synergistic effect under the assumption of 
mutual exclusivity. To be consistent with the classic isobolo-
gram and its equation (interaction index of Berenbaum), he 
decided that mutually exclusive assumption will be used for the 
analysis of drug interaction.
    The Bliss independence and Loewe additivity models are 
the two most cited reference models for determining drug 
interaction [9,10,27,28]. According to Berenbaum, only when the 
dose-response relationship of each drug follows an exponential 
decline with the dose, the two models result in the same 
equation and are consistent with each other [10]. When dose-
response curves are steeper than the exponential model, Bliss 
independence will result in Loewe antagonism; whereas, when 
dose-response curves are less steep than the exponential model, 
Bliss independence will result in Loewe synergism (Fig. 1). 
Greco et al. [10] revealed that they prefer Loewe additivity to 
Bliss independence for the lack of synergism or antagonism. 
When curves are steep ( γ > 2), the Bliss independence criterion 
may overestimate synergism, whereas the Loewe additivity 
model can overemphasize antagonism. That is to say, a class of 
drug interaction is dependent on a reference model because 
a given effect seems to be either synergistic with the Loewe 
additivity or antagonistic with the Bliss independence. However, 
the use of both models is not practical because one of the two 
models could be more plausible than the other [27]. Goldoni 
and Johansson [27] said that although the Loewe additivity 
model is slightly more plausible and is preferred in toxicology, it 
could be incorrect under certain conditions. 
    The interpretation of an assessment of drug interactions by 
the Loewe additivity reference model is free of mechanistic 
restrictions and implications. It is possible to determine that 
the combination of two or more inhibitors is more effective 
than their individual use by means of isobolographic analysis, 
even when no information about their mechanism of action 
is available [29]. Accordingly, the Loewe additivity reference 
model is consistent with the graphical isobologram approach 
[29]. The sigmoidicity of a dose-effect curve greatly magnifies 
the differences among the different methods or theories (Fig. 1). 
Thus, the main controversies in drug combination analysis in 
the past century can be readily resolved [1]. Drug additivity is 
substantiated under the Loewe additivity model but not the 
Bliss independence model [30]. Therefore, the Loewe additivity 
model is a universal reference model for classifying drug 
interaction.
Response surface
    There have been several methods for evaluating drug inter-
action: diagonal array [17], isoboles [9,17,31], isobolar surface 
for three-drug combination [17], interaction index [9,17], and 
response surface [10]. Isobolographic analysis and interaction 
index method are not universally applicable, and they rely on 
the level of effect; one isobole relates only to a single effect, and 
one interaction index does only to a single dose pair. Therefore, 
separate analyses should be conducted at numerous levels (ED5, 
ED25, ED50, ED75, etc.) in order to classify all possible interactions. 
To depict the entire set of levels of effect (from ED1 to ED99), one 
may build all the isoboles in three dimensions, thus, creating a 
surface of isoboles, the so-called response surface. It illustrates 
the drug effect (Z axis) versus two-drug doses (X and Y axes) [10] 
and presents an entire drug interaction at all dose pairs. 
    Over the last decade, drug interaction studies have been 
increasingly evaluated on the basis of a response surface 
model. The approaches to choosing a response surface model 
are empirical or functional [32]. Many examples of response 
surface methods employed a single interaction parameter to 
catch synergy, additivity, or antagonism [33-37]. These models 
are sound if only synergy, additivity, or antagonism exists 
throughout the entire surface; they are incompetent to describe 
the interspersion of regional synergy or regional antagonism in 
different areas of drug combinations [38]. 
    Isoboles are not necessarily consistent or similar because 
they may cross the additivity line so that some combinations 
with a specific effect are synergistic, and others antagonistic. 
Berenbaum maintained that the conclusion as to whether a 
combination has a specific class of drug interaction applies 
to that combination but not to untested combinations [9]. A 
model with a single interaction parameter never reflects an 
inconsistency in the patterns of drug interactions. To solve this 
problem, some researchers proposed a few parametric models 
with a polynomial interaction function for two drugs [38-
40]. The interaction functions capture synergy, additivity, and 
antagonism scattering all over the surface of drug combinations.
Response surface models with a single 
interaction parameter
Greco model [34]
    Assuming the dose-response relationships for two drugs follow 
the sigmoid Emax, the formula of this model is:
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Therefore, when α > 0, the interaction index is less than one, Loewe synergism is indicated, when 
α < 0, interaction index is greater than one, Loewe antagonism is indicated, when α = 0, Loewe 
additivity is indicated. The larger positive α is, the smaller is the interaction index, the stronger the 
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3.1.2  Machado Model  
Machado and Robinson [35] reviewed a set of interaction models which were provided by 
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Plackett and Hewlett. [42]  
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Therefore, when α> 0, the interaction index is less than 1, 
Loewe synergism is indicated; when α< 0, interaction index is 
greater than one, Loewe antagonism is indicated; and when α
= 0, Loewe additivity is indicated. The larger positive α is, the 
smaller the interaction index and the stronger the synergy. 
Machado model
    Machado and Robinson [35] reviewed a set of interaction models 
which were provided by Hewlett [41], and they recommended 
the ensuing model, which was in effect considered by Plackett 
and Hewlett [42]:
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Like the parameter α in the model of Greco et al. [34]. the 
interaction parameter is η. When 0 < η < 1, Loewe synergism 
is indicated; when 1 < η < ∞, Loewe antagonism is indicated; 
and when η= 1, Loewe additivity is indicated. The smaller 
the value of η with 0 < η < 1, the more synergistic is the 
interaction. 
Plummer model
    Plummer and Short [36] used a model, Eq. (14), for identifying 
and quantifying departures from additivity. Their model is a 
generalization of a model with a fixed relative potency derived 
by Finney [33], and it allows relative potency to vary. Their 
model is: 
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Therefore, β4 is the interaction parameter, which captures synergism (β4 > 0), additivity (β4 = 0), and 
antagonism (β4 < 0). The larger positive is β4, the smaller is the interaction index, the stronger the 
synergy. 
3.1.4  Carter model  
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Therefore, β4 is the interaction parameter which captures 
synergism (β 4 > 0), additivity (β 4 = 0), and antagonism (β 4 < 0). 
The larger positive is β 4, the smaller the interaction index, and 
the stronger the synergy.
Carter model 
   The multivariate linear logistic model [43] is very popular in 
the analysis of clinical trial data when the response variables are 
binary or quantal. Carter et al. [37] and Gennings et al. [44] used 
the logistic model for an analysis of drug interactions involving 
continuous data points. They rearranged the general form of the 
logistic model and used the following equation:
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The denominator must be positive. β12 is the interaction parameter, which captures synergism (β12 
> 0), additivity (β12 = 0), or antagonism (β12 < 0). 
There are many other parametric response surface models which have a single interaction 
parameter.  They  could  be  applied  to  the  common  data.  Hewlett  [41]  provided  a  general 
framework  for  deriving  many  specific,  potentially  useful,  multivariate  interaction  models.  All 
response surface models using a single interaction parameter are inappropriate in the situation 
when synergism, additivity, and antagonism intersperse over the entire range of doses (Fig. 3). 
3.2  Response surface models with an interaction function 
3.2.1  Minto model 
 ------- (17).
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The denominator must be positive. β12 is the interaction 
parameter which captures synergism (β 12 > 0), additivity (β 12 = 
0), or antagonism (β 12 < 0).
    There are many other parametric response surface models 
with a single interaction parameter; they can be applied to 
the common data. Hewlett [41] provided a general framework 
for deriving many specific, potentially-useful, multivariate 
interaction models. All response surface models using a single 
interaction parameter are inappropriate in the situation when 
synergism, additivity, and antagonism intersperse over the 
entire range of doses.426 www.ekja.org
Drug interaction Vol. 58, No. 5, May 2010
Response surface models with an interaction 
function
Minto model
    Minto et al. [39] employed the concept of normalizing drug 
concentration to potency. They thought that any ratio (θ) of the 
two drugs acts like a new drug, and a fixed ratio of the two drugs 
(a new drug) has its own sigmoid Emax curve. The sigmoid Emax 
model for a single drug is extended to a model that takes each 
ratio of two drugs as a drug in its own right.
    I will express the concentrations of drugs V and R as [V] and 
[R]. Each drug must be normalized to its potency, C50, and the 
following forms are obtained.
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UV and UR are units of potency, and the normalized concentrations of drug V and R. A set of new 
drugs, each having a unique unit ratio (θ) of UV and UR, is defined in a set of terms of θ. The term 
of θ is defined as  
θ
UR
UV�UR
θ   
When drug V only exist, θ is 0; when drug R only exist, θ is 1. The new drug concentration is 
simply UV + UR. These terms can be combined with sigmoid Emax equation:  
� ��� θ �
�
UV�UR
U���θ��
γ�θ�
���
UV�UR
U���θ��
γ�θ�  , 
where the drug concentration is UV + UR, γ(θ) is the sigmoidicity of the concentration-response 
curve at a specific ratio (θ), U50(θ) is the number of units of potency associated with 50% of 
maximum effect at a specific ratio θ, and  ��� θ  is the maximum drug effect at a specific ratio θ. 
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UV and UR are units of potency, and the normalized concen-
trations of drugs V and R. A set of new drugs, each having a 
unique unit ratio (θ) of UV and UR, is defined in a set of terms of θ. 
The term of θ is defined as 
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------------------------------------- (20).
When only drug V exists, θ is 0; when only drug R exists, θ is 1. 
The new drug concentration is simply UV + UR. These terms can 
be combined with the sigmoid Emax equation: 
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--------------------- (21),
where the drug concentration is UV + UR, then γ(θ) is the 
sigmoidicity of the concentration-response curve at a specific 
ratio (θ); U50(θ) is the number of units of potency associated 
with 50% of the maximum effect at a specific ratio θ; and Emax(θ) 
is the maximum drug effect at a specific ratio θ. The term U50(θ) 
is the potency of drug combination at a specific ratio θ. Because 
one 50% of maximum effect is 1 unit of potency, when only 
drug V (θ = 0) or drug R (θ = 1) is present, the number of units 
associated with one 50% drug effect, U50(0) or U50(1), must be 
one.
    Minto et al. chose the fourth-order polynomial function (f(θ)) 
to allow the interspersion of patterns of drug interactions all 
over the drug combinations. 
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The  forms  of  f(θ)  are  Emax(θ),  U50(θ),  and  γ(θ).  Coefficients  βx  are  model  parameters  that  are 
estimated by the data. The Two terms, β0 and β1 in Emax(θ), U50(θ), or γ(θ), are replaced by other 
terms already defined. 
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If U50(θ) is 1 for all values of θ, the interaction will be additive. If U50(θ) is less than 1 for all values 
of θ, this amplify the term 
UV�UR
U���θ� in Eq. (21). This will create a synergistic effect. If U50(θ) is greater 
than 1 for all values of θ, this lessen the term 
UV�UR
U���θ� in Eq. (21). This will create an antagonistic 
effect. This model can be used in investigating the drug interaction when the maximum effects of 
drugs V and R are not identical.  
 
--------------- (22)
The forms of f(θ) are Emax(θ), U50(θ), and γ(θ). Coefficients β x
are model parameters that are estimated by the data. The two 
terms, β 0 and β 1 in Emax(θ), U50(θ), or γ(θ), are replaced by 
other terms already defined.
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    The functions of parameters for the Minto model are unable to 
interpret the classes of drug interactions which mix themselves 
over the whole response surface. The contours of interaction 
indices will make the interpretation easy by a mere glance at the 
plot. The equation for the interaction index is as follows:
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parameters to help clinicians determine the interaction surface shape, interaction type, the 
maximum interaction point, and interaction curve shape immediately. The Fidler model meets 
Minto’s criteria for an ideal pharmacodynamic interaction model,[39] and is similar to the Finney 
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The term α indicates the type of interaction. Positive values 
show synergy; negative ones show antagonism. The term f 
defines changes in an isobole of the response surface for a given 
level of drug effect. A functional form of the term f inspired by 
the gamma probability distribution gives 
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The term α indicates the type of interaction. Positive values show synergy; negative ones show 
antagonism. The term f defines changes in an isobole of the response surface for a given level of 
drug effect. A functional form of the term f inspired by the gamma probability distribution gives  
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In this function, θ is identical to θ in Minto model, and is given  X
�X�
C����
θ
UA
UA�UB
. The m term 
is the symmetry parameter of the potency ratio θ, where the maximum interaction occurs. The 
interaction scope parameter w specifies the uniformity of the interaction across various drug ratios. 
The parameters γ(θ) and Emax are given as functions of potency fraction 
γ θ γAθ γB θ β β β θ   
��� θ ����Aθ ����B θ ζ ζ ζ θ . 
The linear functions of the potency ratio, γAθ γB θ ����Aθ ����B θ , are simple 
estimates for γ(θ) and Emax. The parameters β and ζ influence the type of change in the linear 
estimates of γ(θ) and Emax. Positive values of β and ζ indicate an increase in γ(θ) and Emax, negative 
indicates a decrease in them, and 0 means no change from the line of estimates of γ(θ) and Emax. 
The  terms,β β β θ ζ β β θ ,  are  restricted  to  be  greater  than  -1  to  keep  each 
function  positive.  The  parameters  mβ  and  mζ  are  the  symmetry  parameters  of  the  respective 
changes, where the maximum changes in γ(θ) and Emax occur; the parameters wβ and wζ are the 
line shape parameters around mβ and mζ, and greater than 0. 
When the Hill slopes of two drugs are different,[21] both Minto and Fidler models deviate 
from  the  classic  additive  interaction  surface  as  given  by  Berenbaum.[9]  Fidler  et  al.[40] 
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, are restricted to be greater than 
-1 to keep each function positive. The parameters mβ and 
m ζ are the symmetry parameters of the respective changes, 
where the maximum changes in γ(θ) and Emax(θ) occur; the 
parameters w β and w ζ are the line shape parameters around m β 
and m ζ, and are greater than 0.
    When the Hill slopes of two drugs are different [21], both 
the Minto and Fidler models deviate from the classic additive 
interaction surface as given by Berenbaum [9]. Fidler et al. 
[40] demonstrated that by assuming a simple linear change in 
the Hill slope as a function of potency fraction, the predicted 
differences between a classical additive interaction state and 
the additive interaction state of the Minto or Fidler model are 
less than experiment error and can be considered negligible. 
    In practical considerations, a direct transformation of the 
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model proposed by Kong and Lee has a square root term and 
the relative potency. So, it can be regarded as a generalization 
of Finney’s model [33] and the model derived by Plummer 
and Short [36]. To construct a generalized model, including 
the nonparallel dose-response curves of two drugs, a varying 
relative potency should be allowed. When the two drugs have 
the nonparallel dose-response curves, or different slopes, each 
drug combination ([V], [R]) on the z-isobole shares the same 
relative potency ρ(z), and its equivalent amount dose is [V] + 
ρ(z) [R] in terms of drug V, or ρ(z)
-1 [V] + [R] in terms of drug R. 
That is, the combination doses on different isoboles may have 
different relative potencies. The form of ρ(z) is derived as 
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[V]iso and [R]iso are the respective single drug doses of drug V and drug R, and together create the 
effect z. To describe the interspersion of interaction modes, Kong and Lee use the following form 
as an interaction function:   
γ δ δ� δ�
�
� δ� ρ
�
� δ� δ�ρ δ� ρ
�
�  , 
where f is an interaction polynomial function of [V] and [R] with parameters γ1 and γ2 capturing 
the  varying  relative  potency  ρ  and  the  coefficients  δ’s.  The  above  polynomial  function  is 
substituted for the interaction parameter (β4) of Plummer model, and the following equation is 
given as  
E
��E β� β� ρ γ δ ρ
�
� . 
Like  the  interaction  index  of  Plummer  model,  the  interaction  index  of  Kong  model  could  be 
derived as the following form:  
  
-------------------------- (31).
[V]iso and [R]iso are the respective single drug doses of drug V 
and drug R, and each of them creates the effect z. To describe 
the interspersion of interaction modes, Kong and Lee use the 
following form as an interaction function: 
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where f is an interaction polynomial function of [V] and [R] with 
parameters γ 1 and γ 2 capturing the varying relative potency 
ρ and the coefficients δ’s. The above polynomial function is 
substituted for the interaction parameter (β 4) of the Plummer 
model, and the following equation is given as 
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Like the interaction index of the Plummer model, the 
interaction index of the Kong model could be derived as the 
following form: 
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When the polynomial function is greater than, equal to, or less than 0, the interaction index is less 
than,  equal  to,  or  greater  than  1,  and  the  resulting  interaction  is  synergistic,  additive,  or 
antagonistic, respectively. 
4  Data analysis 
The analyses of the following data were performed using 7 methods reviewed here. The aim 
of  the  study  was  to  investigate  the  combinations  of  vecuronium  and  rocuronium  to  have 
synergistic interaction. Left phrenic nerve-hemidiaphragms of 48 male Sprague-Dawley rats (150-
250 g in weight) were mounted in Krebs solution.  Supramaximal electrical stimulation (0.2 ms, 
rectangular)  of  50  Hz  for  1.9  s  was  applied  to  the  phrenic  nerve  and  the  evoked  tetanic 
contractions  measured  with  a  force  transducer.  Each  preparation  was  exposed  to  one  of  4 
vecuronium concentrations (0.0, 1.5, 2.5, 3.0 μM), or one of 4 rocuronium concentrations (0.0, 3.0, 
4.5,  5.5  μM).  Subsequently  the  adequate  amount  of,  rocuronium  to  a  vecuronium  bath  or 
vecuronium to a rocuronium bath was cumulatively added until an 80-90% increase of tetanic 
fade was reached.  
In this data set, E0’s of two drugs are 0, and Emax’s are 1 (or 100%). For interaction parameter 
and interaction index of the Greco, and Machado models, the values of Hill slope and potency of 
each drug acting alone were calculated (vecuronium: 6.5125, 2.98 μM, rocuronium: 7.8975, 5.34 μ
M, respectively) and then substituted for ED50’s and γ’s of the two models. Interaction indices of 
  
-----------(34).
 
When the polynomial function is greater than, equal to, or less 
than 0, the interaction index is less than, equal to, or greater 
than 1, and the resulting interaction is synergistic, additive, or 
antagonistic, respectively.428 www.ekja.org
Drug interaction Vol. 58, No. 5, May 2010
Data analysis
    The analyses of the following data were performed using the 7 
methods reviewed here. The aim of the study was to investigate 
the combinations of vecuronium and rocuronium to have 
synergistic interaction. Left phrenic nerve-hemidiaphragms 
of 48 male Sprague-Dawley rats (150-250 g in weight) were 
mounted in Krebs solution. Supramaximal electrical stimu-
lation (0.2 ms, rectangular) of 50 Hz for 1.9 s was applied to 
the phrenic nerve, and the evoked tetanic contractions were 
measured with a force transducer. Each preparation was ex-
posed to one of four vecuronium concentrations (0.0, 1.5, 2.5, 
3.0 μM), or one of four rocuronium concentrations (0.0, 3.0, 4.5, 
5.5 μM). Subsequently the adequate amount of rocuronium to 
a vecuronium bath or vecuronium to a rocuronium bath was 
cumulatively added until an 80-90% increase of tetanic fade 
was reached. 
    In this data set, E0’s of two drugs are 0, and Emax’s are 1 (or 
100%). For interaction parameter and interaction index of 
the Greco, and Machado models, the values of Hill slope and 
potency of each drug acting alone were calculated (vecuronium: 
6.5125, 2.98 μM, rocuronium: 7.8975, 5.34 μM, respectively) 
and then substituted for ED50’s and γ’s of the two models. 
Interaction indices of the Berenbaum method (Eq. (5)) were 
directly calculated using the sigmoid Emax equation substituted 
with the above calculated values. Plummer model (Eq. (14)) 
and Carter Model (Eq. (17)) were fitted with the data by using 
Tablecurve3D
Ⓡ. 
    The iso-effective contours (Fig. 2) and the plot of interaction 
indices of actual data points (Fig. 3) were drawn. All the isoboles 
of the 4 models are upward concave and consistently indicate 
synergistic interaction (Fig. 2). The interaction index of the 
Fig. 2. The Greco model (A), the Machado model (B), the Plummer model (C), and the Carter model (D) show isoboles of the response surface. 
The abscissa is a concentration of vecuronium (μM) and the ordinate, that of rocuronium (μM). The numbers in the plots are the fractional 
increase of tetanic fade. The thick, solid line in panel A is shown as an example of the Loewe additivity line at a 0.9 effect. If all the Loewe 
additivity lines would be drawn, these would reveal that the isoboles are upward concave. Therefore, it is concluded that interactions between 
vecuronium and rocuronium are consistently synergistic.429 www.ekja.org
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Machado model cannot be calculated due to the limitation of 
the model. Table 1 shows the results of five interaction analysis 
methods. Four models, except for the Berenbaum method, 
consistently show interaction indices of less than 1, which 
mean synergistic interaction (Table 1 and Fig. 3). In Fig. 3, the 
Berenbaum method reveals that the interaction indices are 
less than 1 at the high effect region and are greater than 1 at 
the low effect region. According to the Berenbaum method, 
combinations of the two drugs have all types of interaction. 
Therefore, the response surface models with a single interaction 
parameter are inadequate to analyze the data which has 
complicated scatter of different types of drug interactions (Fig. 3 
and 4, Panel A).
    Next, three aforementioned flexible response surface models 
with an interaction function were fitted to the same data using 
Tablecurve3D
Ⓡ, and the parameters, the response surfaces, 
isoboles, and contours of the interaction index of each model 
were determined, and plots were made for seeking the 
differences of their results (Fig. 4 and 5). The functions for the 
parameters U50(θ) and γ(θ) of the Minto model were calculated 
and illustrated (Fig. 6). The full model (10 parameters) for the 
Minto model was analyzed; the Fidler model (9 parameters) 
was analyzed when w = 1; and the Kong model (8 parameters) 
was analyzed when the relative potency ratio was constant. The 
isobole plot of raw data is rendered via Renka I (nonparametric 
algorithm) procedure, and it is shown in Fig. 4, panel A. 
Pharmacodynamic parameters of response surface models 
are listed at Table 2. The values are different depending on the 
model. In the Kong and Plummer models, because relative 
potency ratio is constant, the Hill slopes of each model are 
identical. 
    The isobole plots of the Minto model, Fidler model, and 
Kong model were relatively similar to the isobole plot of raw 
data. Minto et al. determined the pattern of drug interaction 
based on the functions of Emax, U50(θ), and γ(θ), especially the 
value of U50(θ) (Fig. 6). The isobole plot of the Minto model is 
shown in Fig. 4, panel B. In this article, with the equation of the 
interaction index, the contour plot of the interaction index (Fig. 5, 
panel A) can be illustrated and help to make the quantitative 
evaluation. Chou and Hayball [45] proposed that an interaction 
index from 0.9 to 1.1 is designated as being additive. In the 
Minto model, the lower extreme effect region has greater 
synergistic interaction. Chou [13] said that for anticancer or 
antiviral agents, synergy at high effect levels (fa > 0.8) is more 
relevant to therapy than at low effect levels (fa < 0.2). On the 
contrary, in the anesthetic area, synergy at low effect levels may 
be more crucial than at high levels because the residual effects 
of anesthetic agents could threaten the safety of patients. 
    In the Fidler model, the pattern of drug interaction is 
determined based on contour of iso-effective combinations, 
contour of interaction index, a direct transformation of the α
term (% contribution of α on a 50% effect), and the best ratio 
for synergistic effect. The isobologram (Fig. 4, panel C) shows 
the deepest upward concavity around the combination of the 
Fig. 3. The plot of interaction indices of actual data points was 
drawn. The interaction index of the Machado model cannot be 
calculated due to the limitation of the model. Four models, except 
for the Berenbaum method, consistently have interaction indices 
of less than 1, which means synergistic interaction. The Berenbaum 
method reveals that most interaction indices are less than 1 at a high 
effect region, and are greater than 1 at a low effect region. According 
to the Berenbaum method, combinations of the two drugs have all 
types of interaction. Therefore, the response surface models with a 
single interaction parameter are inadequate in analyzing data which 
has a complicated scatter of different types of drug interactions.
Table 1. Five Methods for Detecting Drug Interactions in Combined Vecuronium and Rocuronium
Model
Drug interaction parameter 
Estimated value 95% CI Result
Synergy Additivity Antagonism
Berenbaum IaI
Greco model
Machado model
Plummer model
Carter model
IaI  1
α > 0
0 < η< 1
β 4 > 0
β 12 > 0
IaI = 1
α = 0
η = 1
β 4 = 0
β 12 = 0
IaI > 1
α < 0
η > 1
β 4 < 0
β 12 < 0
0.881
0.684
0.816
0.363
0.125
[0.857, 0.905]
[1.199, 0.168]
[0.785, 0.846]
[0.232, 0.495]
[0.088, 0.162]
Sy
Sy
Sy
Sy
Sy
Estimated value of Berenbaum is mean of IaI’s. IaI indicates interaction index by Berenbaum method, Sy indicates synergy, CI indicates confi-
dence interval. 430 www.ekja.org
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unit ratio of 0.78 : 0.22, vecuronium : rocuronium (Table 2). The 
interaction indices range from 1 to 0.78. According to Chou 
and Hayball [45], the contour plot of interaction index (Fig. 5, 
panel B) reveals synergistic interaction, except for the area in 
which the combination of two drugs has a higher concentration 
of rocuronium than of vecuronium. A direct transformation of 
the α term (% contribution of α on a 50% effect) is 5% in this 
data set. In other words, the interaction of vecuronium and 
rocuronium requires 95% of the additive drug combination to 
produce the 50% effect at the most effect ratio. The minimum 
interaction index (0.78) is in about a 99% effective zone. The way 
in which to make this discrepancy has not been determined 
within the course of this research.
    In the Kong model, it is assumed that relative potency is 
constant (that is, two drug dose-effect curves are parallel) like 
the analysis of the Plummer model. The shape of isobole in 
this model is most similar to that in the raw data among seven 
models (Fig. 4, panel A and D). The pattern of drug interaction is 
determined based on isobole plot, contour of interaction index, 
and polynomial function (not seen here). According to the 
Chou and Hayball [45], the isobologram (Fig. 4, panel D) shows 
synergistic, additive, and antagonistic interactions, and the 
interaction indices range from more than 1 to less than 0.6 (Fig. 
5, panel C). The extreme effect regions get greater synergistic 
interaction. 
    The distribution of patterns of drug interaction depends on 
a response surface model. Which model best approximates 
the information in data should be decided using the model 
selection. 
Model selection
    The information scientists want to reveal is in the observed 
data. It has been expressed as a model. Making valid inferences 
from scientific data depends on a model of the information in 
the data [46]. For selecting the best model, it is assumed that 
Fig. 4. This figure shows isoboles of the response surface derived from raw data (A), Minto model (B), Fidler model (C), and Kong model (D). 
The isoboles of raw data (A) are rendered via the Renka I (nonparametric algorithm) procedure. The abscissa is a concentration of vecuronium 
(μM) and the ordinate, that of rocuronium (μM). The numbers in the plots are the fractional increase of tetanic fade. If the Loewe additivity line 
would be drawn, this would reveal what type of drug interaction the isobole has. 431 www.ekja.org
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there are data and a priori set of models and that statistical 
inference is to be model-based.
    Researchers should conceive many models (i.e., multiple 
working hypotheses) and at the same time, cope with how 
to choose among the possibilities. The approaches to model 
selection use classical hypothesis testing [47], the Akaike 
information criterion (AIC) [48], the Bayesian information 
criterion (BIC) [49], and cross validation, etc. [46]. Generally, 
Fig. 6. The functions for the parameters U50(θ), and γ(θ) for the two drug interaction show a synergistic interaction (U50(θ)=0.6934) at θ=0.36, 
which is the ratio of the potency unit of 0.64 : 0.36, vecuronium : rocuronium (A), and varying steepness depending on the unique ratio of two 
drugs (B).
Fig. 5. The contours of the interaction index calculated based on the 
Minto model (A), Fidler model (B), and Kong model (C) are plotted. 
The value “1.0” in the contour plot of the interaction indices represents 
additivity; the values less than 1.0 represent synergistic interaction; 
and the ones more than 1.0 represent antagonistic interaction. Chou 
and Hayball proposed that an interaction index from 0.9 to 1.1 is 
designated as being additive. Based on the Minto and Fidler models, 
the interactions of the two drugs are synergistic and additive. By the 
Kong model, the interactions of the two drugs are synergistic, additive, 
and antagonistic. The interspersion of the interaction indices on the 
entire surface is relatively different among three models. The abscissa 
is a concentration of vecuronium (μM) and the ordinate, that of 
rocuronium (μM).432 www.ekja.org
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hypothesis testing is a very poor basis for model selection [48], 
especially, tests between models that are not nested [46]. In 
cross validation, the data are divided into two partitions, the first 
partition is used for model fitting; and the second one is used 
for model validation. A new partition is continuously selected, 
and this whole process is repeated hundreds or thousands of 
times. This method may be an alternative method for model 
selection but is time-consuming. 
    The target models of AIC and BIC are different [50]. The target 
model of AIC is specific to the sample size; it is the best model 
to minimize the estimated Kullback-Leibler information loss 
[51,52] when models are used to approximate the full reality (or 
truth). This target model depends on the change of sample size. 
Even the priori set of models may change when the sample size 
changes greatly. In contrast with AIC, the derivative assumption 
of BIC is that there is a true model in a model set. A true model 
is one that generates the data, independent of data size. The 
target model of BIC is the true model. The goal of model 
selection is to obtain a perfect model so that no information 
is lost in fitting data to a model of the information in data. It is 
impossible to achieve this ideal purpose because models are 
only approximations. However, AIC helps us choose the best 
model, which loses as little information as possible and allows 
the efficient and objective filtration of information from noise 
[46]. 
    The principle of parsimony is that model selection is a bias 
versus variance trade-off. A parsimonious model must be as 
simple as possible in terms of variables and model structure. 
Inference from a model with too few variables may be biased, 
and inference from a model with too many variables may not 
be precise and can result in spurious conclusions. Parsimony 
lies between underfitting and overfitting [46]. For linear models, 
such as multiple regression, a minimum of 10 to 15 observations 
(or events) per predictor variable will generally allow good 
estimates [53-56]. Many researchers do not notice the problem 
of overfitting in regression-type modeling. Overfitting results 
in overly-optimistic findings that do not present in the real 
population and will not reproduce in a future data set. Although 
overfitting is not a bad beginning to seek a good model, 
spurious conclusions generated by overfitted model may lead 
doctors the wrong way in clinical decision-making. 
    In this article, 7 models are introduced, and the last 3 models 
have several nested submodels. A model should be selected to 
best fit a dose-effect data set using AIC, not hypothesis testing.
Summary
    In anesthetic practice, anesthesiologists administer multiple 
drugs to patients simultaneously. They have been long aware of 
the importance of drug interaction and have performed many 
investigations for the efficient combination of anesthetic agents. 
The study of drug interaction is aiming at choosing the optimal 
drug combination. 
    Determining what pattern of drug interaction is acting is 
dependent on a reference model [10]. Although further study 
should be continued, Loewe additivity is a universal reference 
model for the classification of drug interaction. The reference 
model has been established, and then, many analytic models 
for drug interaction were proposed to be validated for their 
performances.
    A lot of models have prevailed. In the anesthetic area, models 
with a single interaction parameter or flexible models with an 
interaction function are adequate to be applied to analyzing the 
data of anesthetic drug interaction. Due to detecting the best 
approximating model among the aforementioned models, AIC 
is the most popular approach for choosing the best model. 
    However good a chosen model may be, it never finds out the 
truth which generates the data set, and, of course, it is uncertain 
whether a chosen model is the best model for approximating 
information in the data. Instead of making an inference from 
only a chosen model estimated as the best, a more robust 
inference can be extracted from averaging several models that 
are considered relevant. This procedure is called multimodel 
inference [57], and this concept needs further study.
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